International Edition
Latest News
Health

Eisai and Biogen Announced New Clinical Trial Findings on Nov

Eisai and Biogen announced new clinical trial findings on Nov. 19, 2026, showing that their treatment lecanemab slowed clinical decline in early Alzheimer's disease patients with alpha-synuclein co-pathology. The companies presented the post hoc analysis from the Clarity…

Eisai and Biogen Announced New Clinical Trial Findings on Nov

Eisai and Biogen announced new clinical trial findings on Nov. 19, 2026, showing that their treatment lecanemab slowed clinical decline in early Alzheimer’s disease patients with alpha-synuclein co-pathology.

The companies presented the post hoc analysis from the Clarity AD cerebrospinal fluid substudy at the 19th Clinical Trials on Alzheimer’s Disease conference, held in Boston and online, according to Biogen. Researchers investigated whether patients carrying aggregated alpha-synuclein protein deposits alongside amyloid beta and tau still benefit from the amyloid-targeting antibody.

Among 623 cerebrospinal fluid samples screened using the Amprion SYNTap seed amplification assay, the prevalence of alpha-synuclein pathology reached 20.4% in participants who tested positive for amyloid beta, compared to 10.0% in amyloid-negative individuals, PR Newswire reported. Patients testing positive for alpha-synuclein also showed a higher baseline amyloid burden, averaging 86 Centiloids compared to 67 Centiloids for those without it, Quiver Quantitative noted.

The 18-month evaluation included 400 participants in the overall tested group and 82 participants in the alpha-synuclein positive subgroup. Lecanemab reduced clinical decline versus placebo across multiple standard assessment scales in both populations.

Eisai biogen lockup rgb side by side
Photo: prnewswire.com
Decline Reduction Versus Placebo at Month 18
Clinical Assessment Scale Overall Clarity AD Population Overall Alpha-Syn-Tested Group Alpha-Syn-Positive Group
CDR-SB Score 27% 26% 41%
ADAS-Cog14 Score 26% 45% 43%
ADCS MCI-ADL Score 37% 30% 43%

While the data links alpha-synuclein co-pathology to faster clinical worsening, the findings indicate that lecanemab preserves cognitive and functional abilities despite the presence of multiple protein pathologies. Eisai leads global development and regulatory submissions for the drug, marketed as Leqembi, while both companies share commercialization responsibilities.

Lecanemab has secured approvals in 53 countries and regions, including the United States, Japan, China, Europe, South Korea, Taiwan, and Saudi Arabia, PR Newswire detailed. Maintenance dosing regimens have also expanded following intravenous approvals in nine countries and recent regulatory clearances for subcutaneous delivery options in the United States, China, and Japan.

Clinical evaluations continue through public-private partnerships such as the AHEAD 3-45 study in preclinical Alzheimer's disease and the Tau NexGen study for dominantly inherited forms of the condition.

Alpha-synuclein is a neural protein that can fold abnormally and form Lewy bodies, which serve as a pathological hallmark of Parkinson’s disease and dementia with Lewy bodies. In Alzheimer’s disease, these abnormal proteins can coexist alongside amyloid beta and tau pathologies.

Researchers used the Amprion SYNTap seed amplification assay to detect abnormally structured alpha-synuclein aggregates within cerebrospinal fluid samples collected during screening and baseline evaluations.

Eisai Co., Ltd., the Japanese pharmaceutical company leading global development and regulatory submissions for lecanemab, was established in 1941 and employs about 10,000 people, with 1,500 in research. The company received its first U.S. FDA approval in 1996 for Aricept (donepezil), an Alzheimer’s treatment co-marketed with Pfizer that accounted for 40% of Eisai’s revenue as of March 2010.

While researchers know that co-pathology contributes to clinical heterogeneity and faster disease progression, its exact clinical relevance in patients receiving amyloid-targeting therapy remains under active investigation.

About the author: Health Desk

Health Desk at Archynewsy.